Wells Fargo & Company Synlogic, Inc. Transaction History

Wells Fargo & Company

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.42 - $0.68 $0 - $1	2 Added 0.38%	524 $0
Q1 2023 May 12, 2023	BUY	$0.56 - $1.07 $114 - $219	205 Added 64.67%	522 $0
Q4 2022 Feb 13, 2023	BUY	$0.58 - $17.99 $5 - $161	9 Added 2.92%	317 $0
Q3 2022 Nov 14, 2022	SELL	$0.91 - $14.63 $36 - $585	-40 Reduced 11.49%	308 $0
Q2 2022 Aug 12, 2022	BUY	$0.89 - $2.47 $26 - $74	30 Added 9.43%	348 $0
Q1 2022 May 16, 2022	BUY	$1.63 - $2.55 $3 - $5	2 Added 0.63%	318 $1,000
Q4 2021 Feb 14, 2022	BUY	$2.27 - $3.0 $229 - $303	101 Added 46.98%	316 $1,000
Q3 2021 Nov 15, 2021	SELL	$2.45 - $4.1 $34 - $57	-14 Reduced 6.11%	215 $1,000
Q2 2021 Aug 16, 2021	BUY	$3.0 - $4.39 $336 - $491	112 Added 95.73%	229 $1,000
Q1 2021 May 13, 2021	SELL	$2.2 - $5.05 $2 - $5	-1 Reduced 0.85%	117 $0
Q4 2020 Feb 09, 2021	BUY	$1.85 - $2.54 $16 - $22	9 Added 8.26%	118 $0
Q3 2020 Nov 05, 2020	SELL	$1.85 - $2.57 $484 - $673	-262 Reduced 70.62%	109 $0
Q2 2020 Aug 13, 2020	SELL	$1.59 - $2.51 $42,252 - $66,700	-26,574 Reduced 98.62%	371 $0
Q1 2020 May 14, 2020	BUY	$1.39 - $3.19 $37,453 - $85,954	26,945 New	26,945 $46,000

25.5K

Ticker SYBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,229,600
Market Cap $103M
Description
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase I...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.